SHR-A1904, ADC e Targeting ea CLDN18.2, e Bontša Ts'ebetso e Tšepisang ea ho Loantša Hlahala ho Kankere e Tsoetseng Pele ea Mala/Gastroesophageal Junction: Liphetho tsa Teko ea Mokhahlelo oa 1

Ka la 16 Phupu, koranta ea machaba ea maemo a holimo ea Nature Medicine e phatlalalitse lintlha tsa lipatlisiso mabapi le SHR-A1904, e leng conjugate ea antibody-drug (ADC) e shebaneng le claudin 18.2 (CLDN18.2), bakeng sa kalafo ea kankere e tsoetseng pele ea mpa kapa kankere ea gastroesophageal junction (GC/GEJC). Bafuputsi ba entse teko ea pele ea bongaka ea Mokhahlelo oa 1 ho batho, ea mekhahlelo e meraro, ho lekola katleho ea SHR-A1904 ho bakuli ba 95 ba neng ba kile ba phekoloa ka kankere e tsoetseng pele ea CLDN18.2-positive G/GEJ.​

6168635e7482e05a7c866386248f989.png

Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.

Nomoro ea mohala: 4008803716

Nomoro ea WeChat: 17801183037

Email:myimmnet@163.com

Claudin-18 isoform 2 (CLDN18.2), protheine e tiileng e kopanang e hlahisoang ka har'a epithelium ea mpa e sa hlaseleng 'me e pepesehetse holim'a lisele tsa hlahala nakong ea phetoho e mpe, ke sepheo se tšepisang sa kalafo bakeng sa mofetše oa mpa le oa gastroesophageal junction (G/GEJ). SHR-A1904 ke motsoako oa antibody-drug o nang le antibody ea monoclonal e shebaneng le CLDN18.2, mojaro o moholo oa inhibitor ea DNA topoisomerase I le khokahano e thehiloeng ho peptide e ka tabohang.

Mokhahlelong oa keketseho ea tekanyo (0.6–8.0 mg kg−1), chefo e fokotsang tekanyo e ile ea bonoa ho bakuli ba babeli ba 4.8 mg kg−1 (febrile neutropenia ea sehlopha sa 3 le keketseho ea bilirubin maling ea sehlopha sa 3) le ho mokuli a le mong ea 6.0 mg kg−1 (leqeba la mucosal ea gastric ea sehlopha sa 3). Tekanyo e phahameng ka ho fetisisa e mamelloang ha ea ka ea fihlelloa, 'me 6.0 mg kg−1 le 8.0 mg kg−1 li khethiloe bakeng sa katoloso ea pharmacokinetic le katleho. Liketsahalo tse mpe tse hlahelletseng tsa kalafo li etsahetse ho bakuli bohle ba 95, hangata e le khaello ea mali (72 (75.8%)), ho nyekeloa ke pelo (64 (67.4%), hypoalbuminemia (61 (64.2%) le ho fokotseha ha palo ea lisele tse tšoeu tsa mali (56 (58.9%)). Ho phaella moo, bakuli ba 59 (62.1%) ba bile le liketsahalo tse mpe tse amanang le lithethefatsi tsa sehlopha sa 3 kapa ho feta. Ha ho mafu a amanang le kalafo a tlalehiloeng. Har'a bakuli ba hlahlojoang ka karabelo, sekhahla sa karabelo se tiisitsoeng se netefalitsoeng e ne e le 24.2% (95% nako ea kholiseho (CI), 11.1–42.3) ho 6.0 mg kg−1 le 25.0% (95% CI, 12.1–42.2) ho 8.0 mg kg−1. Nako e mahareng ea ho phela ntle le tsoelo-pele e ne e le likhoeli tse 5.6 (95% CI, 3.0–6.9) ho 6.0 mg kg−1 le likhoeli tse 5.8 (95% CI, 3.0–8.6) ho 8.0 mg kg−1. Qetellong, SHR-A1904 e bontšitse boemo ba polokeho bo laolehang le ho khothaletsa ts'ebetso ea ho loantša hlahala ho bakuli ba nang le mofetše oa G/GEJ oa CLDN18.2-positive, e leng se hlokang lipatlisiso tse ling.

4afe11cbdef51c2de0f28bc0f28e551.png

Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.

Nomoro ea mohala: 4008803716

Nomoro ea WeChat: 17801183037

Email:myimmnet@163.com

微信图片_20241115181717


Nako ea poso: Phupu-24-2025